Aceneuramic Acid Extended-Release Tablets
UX001-CL302
Phase 3 small_molecule terminated
Quick answer
Aceneuramic Acid Extended-Release Tablets for Hereditary Inclusion Body Myopathy is a Phase 3 program (small_molecule) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx Pharmaceutical
- Indication
- Hereditary Inclusion Body Myopathy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated